Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

Wang, P, Dong, Q, Zhang, C, Kuan, P-F, Liu, Y, Jeck, W R, Andersen, J B, Jiang, W +18 more·2013·Oncogene
DOI 10.1038/onc.2012.315

Cited by (398)

Items 301–398 of 398

  1. A perioperative study of Safusidenib in patients with IDH1 -mutated glioma
    Sarah A. Cain, Monique D. Topp, Mark Andrew Rosenthal, Robert Tobler, Saskia Freytag, Sarah A. Best, James Richard Whittle, Katharine Jann Drummond · 2024 · Future Oncology
  2. Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas
    Peng Wang, Yanwei Liu, Lin Zhi, Xiaoguang Qiu · 2021 · Frontiers in Oncology
  3. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy
    Zachary J. Brown, Samantha M. Ruff, Timothy Michael Pawlik · 2023 · Expert Review of Anticancer Therapy
  4. Molecular genetic aspects of intrahepatic cholangiocarcinoma: literature review
    Beslan Nuralievich Gurmikov, Yu. A. Kovalenko, Vladimir Aleksandrovich Vishnevsky, Alexey V. Chzhao · 2019 · Advances in molecular oncology
  5. Molecular Characteristics of Biliary Tract and Primary Liver Tumors.
    S. Tsai, T. Gamblin · 2019 · Surgical Oncology Clinics of North America
  6. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers
    Ruyi Zhang, Marco Puzzoni, Stefano Mariani, Yi Zheng, Nicole Liscia, Yixuan Guo, Clelia Donisi, Yu Liu, Valentino Impera, Weijia Jia Fang et al. · 2021 · Cancer Science
  7. Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development
    Mari Nakazawa, Waqar Arif, Ezra G. Baraban, Andrés Matoso, Elsa Hallab, Emma Kartalia, Nilofer Saba Azad, Marina Baretti, Daniel J. Zabransky, Robert A. Anders et al. · 2025 · npj Precision Oncology
  8. Morphologic and immunohistochemical characterization of small and large duct cholangiocarcinomas in a Western cohort: A panel of pCEA, CRP, N-cadherin, and albumin in situ hybridization aids in subclassification
    Raymond Gong, Zongming E. Chen, Karen E. Matsukuma · 2025 · Annals of Diagnostic Pathology
  9. Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma.
    Younghoon Kim, Jae-Min Song, Namkyoung Kim, Taebo Sim · 2025 · RSC Medicinal Chemistry
  10. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
    Tianyu Wu, Xiaoqing Jiang, Xin Zhang, Bodeng Wu, Bin Xu, Xiaoliu Liu, Lei Zheng, Yu Wang · 2021 · Cancer Control
  11. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development
    Amir Ata Rahnemai‐Azar, Timothy Michael Pawlik · 2021 · Expert Opinion on Investigational Drugs
  12. Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas
    Eric Lipp, Roger E. McLendon · 2018 · Seminars in Oncology Nursing
  13. Identification of target genes co-regulated by four key histone modifications of five key regions in hepatocellular carcinoma
    Yu-Xian Liu, Jia‐Le Song, Xiaoming Li, Hao Lin, Yanni Cao · 2024 · Methods
  14. Fighting Fire with Fire in Cancer
    Thorsten Berger, Mary E. Saunders, Tak W. Mak · 2015 · Springer eBooks
  15. mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation
    Laura Wiehle, Günter Raddatz, Stefan Pusch, Julian Gutekunst, Andreas von Deimling, Manuel Rodríguez‐Paredes, Frank Lyko · 2017 · Cell Stress
  16. Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review
    Peixin Huang, Yingting Zhou, Yi Chen · 2021 · Journal of Gastrointestinal Cancer
  17. Targeting IDH1 mutation-driven Nrf2 signaling to suppress malignant behavior in fibrosarcoma cells
    Seoyeon Park, Kyung‐Soo Chun, Do‐Hee Kim · 2025 · Toxicological Research
  18. Cancer Stem Cells and Aldehyde Dehydrogenase 1 in Liver Cancers
    Hiroyuki Tomita, Tomohiro Kanayama, Ayumi Niwa, Kei Noguchi, Kazuhisa Ishida, Masayuki Niwa, Akira Hara · 2017 · InTech eBooks
  19. Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities
    Dan Høgdall, Colm J. O’Rourke, Jesper Bøje Andersen · 2022 · Advances in cancer research
  20. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility
    Watcharin Loilome, Nisana Namwat, Apinya Jusakul, Anchalee Techasen, Poramate Klanrit, Jutarop Phetcharaburanin, Arporn Wangwiwatsin · 2023 · Recent results in cancer research/Recent Results in Cancer Research
  21. IDH1‐mutated Crohn's disease‐associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated‐type dysplasia
    Camilla Guerini, Daniela Furlan, Giuseppina Ferrario, Federica Grillo, Laura Libera, Giovanni Arpa, Catherine Klersy, Marco Vincenzo Lenti, Roberta Riboni, Enrico Solcia et al. · 2023 · Histopathology
  22. Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
    Florence Pasquier, Claude Chahine, Christophe Marzac, Stéphane de Botton · 2020 · Expert Review of Precision Medicine and Drug Development
  23. Epigenetic Reduction of DNA Repair in Progression to Cancer
    Carol Bernstein, Harris Bernstein · 2015 · InTech eBooks
  24. Cholangiocarcinoma and Gallbladder Cancer
    Anuj Kishor Patel, Weijing Sun · 2016 · WORLD SCIENTIFIC eBooks
  25. Hot topics in cholangiocarcinoma
    Giovanni Brandi · 2019 · Translational Cancer Research
  26. Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models
    Ashley V. Schwartz, Grace Chao, Mikella Robinson, Brittany M. Conley, Mowaffaq Adam Ahmed Adam, Grace A. Wells, An D. Hoang, Elene Albekioni, Cecilia Gallo, Joi L. Weeks et al. · 2025 · Journal of Biological Chemistry
  27. Bile cell-free DNA shows benefit as a potential sample for somatic mutation detection of resectable cholangiocarcinoma
    Songyao Liu, Xiaowu Ma, Hongkai Zhuang, Bingkun Wang, Qingbin Wang, Yonglin Hua, Ziyu Zhang, Yuxin Xiao, Jian‐Bo Wan, Yajin Chen et al. · 2025 · iLiver
  28. The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
    Tianying Zhang, Hengtong Han, Yating Zhang, Tingting Zhang, Libin Ma, Ze Yang, Yong-xun Zhao · 2026 · Cell Death Discovery
  29. Recent advances in targeted and immunotherapeutic strategies for cholangiocarcinoma: A comprehensive review
    Xuan-Yi Lin, Jian-Biao Zhou, Kan Yonemori, Xiaochen Zhang, Jian Ruan, Yun-Lu Jia · 2026 · Genes & Diseases
  30. Research on Targeted Therapy for Malignant Tumors of the Biliary Tract
    Yuxin Yang, Hutianyu Zhong, Jingjing Zhang, Peng Wang · 2026 · OncoTargets and Therapy
  31. A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation
    Suneel Deepak Kamath, Xiaoqi Lin, Aparna Kalyan · 2018 · The Oncologist
  32. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions
    Kwun Wah Wen, Peter S. Rabinovitch, Dongliang Wang, Aras N. Mattis, Linda D. Ferrell, Won‐Tak Choi · 2020 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  33. Molecular-driven treatment for biliary tract cancer: the promising turning point
    Mara Persano, Marco Puzzoni, Pina Ziranu, Valeria Pusceddu, Eleonora Lai, Andrea Pretta, Clelia Donisi, Giovanna Pinna, Dario Spanu, Erika Cimbro et al. · 2021 · Expert Review of Anticancer Therapy
  34. Involvement of Epigenomic Factors in Bile Duct Cancer
    Magdalena Rogalska, Jesper Bøje Andersen · 2022 · Seminars in Liver Disease
  35. Platinum Sensitivity inIDH1/2Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal
    Deborah B. Doroshow, Wei Wei, Meenakshi Mehrotra, Daniella Sia, Joseph P. Eder, Ranjit S. Bindra, Jane Houldsworth, Patricia Mucci LoRusso, Zenta Walther · 2023 · Cancer Investigation
  36. Impact of genetic alterations on long-term outcomes in resectable intrahepatic cholangiocarcinoma: meta-analysis
    Fabio Giannone, Fabio Del Zompo, Antonio Saviano, Erwan Pencreach, Catherine Schuster, Thomas F. Baumert, Patrick Pessaux · 2024 · British journal of surgery
  37. Cholangiocellular Cholangiocellular carcinoma today. Literature review
    Д. Л. Ротин · 2015 · Malignant tumours
  38. Accuracy of 1H magnetic resonance spectroscopy for quantification of 2-hydroxyglutarate using linear combination and J-difference editing at 9.4 T
    Ulf Neuberger, Philipp Kickingereder, Xavier Helluy, Manuel Dominik Fischer, Martin Bendszus, Sabine Heiland · 2017 · Zeitschrift für Medizinische Physik
  39. Review of IDH mutations and potential therapies for intrahepatic cholangiocarcinoma
    Samantha M. Ruff, Mary Dillhoff · 2023 · Hepatoma Research
  40. Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé
    Zsolt Szakács, Hussain Alizadeh · 2022 · Hematológia–Transzfuziológia
  41. Editorial: Role of imaging in biliary tract cancer: diagnosis, staging, response prediction and image-guided therapeutics
    Pankaj C. Gupta, Avinash R. Kambadakone, Bhawna Sirohi · 2024 · Frontiers in Oncology
  42. Established and Emerging Biomarkers for Prediction, Early Detection, and Prognostication of Cholangiocarcinoma
    Andrés García-Sampedro, Pilar Acedo, Stephen P. Pereira · 2021 · Springer eBooks
  43. Targeted therapies and immunotherapies for unresectable cholangiocarcinoma
    Shengbai Xue, Weihua Jiang, Jingyu Ma, Haiyan Xu, Yanling Wang, Wenxin Lu, Daiyuan Shentu, Jiujie Cui, Maolan Li, Liwei Wang · 2025 · Chinese Medical Journal
  44. Oncogenesis in cholangiocarcinoma
    Rares Ilie Orzan, Andrada Seicean · 2025 · Advances in clinical chemistry
  45. Genetic Uncertainties Fueling Cholangiocarcinoma Progression
    Sunil Kumar Kadiri, Prashant Kumar Tiwari · 2026 · Current Genomics
  46. Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy
    Pengcheng Wang, Ning Li, Yuhang Ye, Jing Pu, Rongqi Sun, Chubin Luo, Zhiqiang Hu, Zhihuan Zhou, Jia Li, Jixue Zou et al. · 2026 · The Oncologist
  47. Understanding cholangiocarcinoma: molecular landscape, pathological classification, and challenges in biopsy diagnosis
    Yoh Zen · 2026 · Histopathology
  48. Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma
    Vivian Valeria Altiery De Jesus, Timothy McMahon, Sara E. Young, Daniel J. Zabransky, Mark M. Yarchoan, Marina Baretti · 2026 · The Oncologist
  49. A Nexus model of cellular transition in cancer
    Mukesh Yadav, Payal Chatterjee, Simran Tolani, Jaya L Kulkarni, Meenakshi Mulye, Namrata Chauhan, Aditi Sakhi, Sakshi Gorey · 2018 · Biological Research
  50. Management of Primary Malignant Hepatic Neoplasms Other Than Hepatocellular Cancer
    Epameinondas Dogeas, Michael A. Choti · 2019 · Elsevier eBooks
  51. Molecular Pathogenesis: From Inflammation and Cholestasis to a Microenvironment-Driven Tumor
    Eleonora Milani, Mario Strazzabosco, Luca Fabris, Massimiliano Cadamuro · 2019 · Springer eBooks
  52. Cancer Metabolism
    Daniel Richard Wahl, Sriram Venneti · 2017 · Springer eBooks
  53. Molecular pathogenesis of biliary tract cancer
    Jason Keith Sicklick, Paul Timothy Fanta · 2017 · Elsevier eBooks
  54. Personalized Medicine in Advanced Cholangiocarcinoma
    Anuhya Kommalapati, James B. Yu, Richard Kim · 2020 · touchREVIEWS in Oncology & Haematology
  55. Mutant IDH uncouples p53 from target gene regulation to disable tumor suppression
    Cole P Martin, William B. Sullivan, Jacqueline A. Brinkman, Deena M Scoville, Jossie J. Yashinskie, Sha Tian, Riccardo Mezzadra, Yu-Jui Ho, Richard P. Koche, Timour Baslan et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  56. Epigenetic basis for the oncogenic potential of IDH mutations
    Chao Lü · 2013
  57. Etiology and Pathogenic Pathways of Cholangiocarcinoma
    Arthur Zimmermann · 2016 · Springer eBooks
  58. NEURLOGICAL OUTCOME OF GLIOMAS; BY MEASURING KARNOFSKY SCORE BEFORE AND AFTER SURGERY
    Muhammad Usman Khalid, Umer Farooq Raina, Dr. Ejaz Ahmad, Dr. Khaleeq Uz Zaman · 2016 · The Professional Medical Journal
  59. Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma
    Colm J. O’Rourke, Letizia Satriano, Douglas V.N.P. Oliveira, Patricia Muñoz-Garrido, Jesper Bøje Andersen · 2019 · Elsevier eBooks
  60. Advances in the molecular characterization of liver tumors
    Matthias Sebastian Matter, Jesper Bøje Andersen · 2017 · Elsevier eBooks
  61. Gut Microbiome and Liver Cancer
    John C. McVey, Qianfei Zhang, Tim F. Greten, Chi Ma · 2021 · Physiology in health and disease
  62. Precision Medicine for Pancreatic Cancer and Cholangiocarcinoma
    Chigusa Morizane · 2021 · Springer eBooks
  63. Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer
    Monica Valente, Alessia Covre, Anna Maria Di Giacomo, Michele Maio · 2021 · Springer eBooks
  64. Biliary Cancer
    Giuseppe Tonini, Michele Iuliani, Giulia Ribelli, Sonia Simonetti, Francesco Pantano · 2021 · UNIPA Springer series
  65. Etiology and Pathogenic Pathways of Cholangiocarcinoma
    Arthur Zimmermann · 2016 · Springer eBooks
  66. Faculty Opinions recommendation of Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
    Mitesh J. Borad · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  67. NEURLOGICAL OUTCOME OF GLIOMAS
    Muhammad Khalid, Umer Farooq Raina, Ejaz Ahmad, Khaleeq-Uz- Zaman · 2016 · The Professional Medical Journal
  68. Cancer suppression by ferroptosis and its role in digestive system tumors
    Jiajia Li, Xuanping Xia, Limin Wu, Zheng Gang Zhu, Yu-Ning Shi, Xu‐Chao Zhang, Yu-Shan Xia, Guangrong Lu · 2022 · World Chinese Journal of Digestology
  69. Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer
    Monica Valente, Alessia Covre, Anna Maria Di Giacomo, Michele Maio · 2022 · Springer eBooks
  70. Identification of a immune-related gene signature as a novel prognostic biomarker of cholangiocarcinoma
    Yutong Zhou, Xun Ran, Min Han · 2023 · Research Square
  71. Mechanism of postoperative recurrence and metastasis of intrahepatic cholangiocellular carcinoma and clinical prevention and treatment strategy
    Xia Sheng, Jian-Min Qin · 2023 · World Chinese Journal of Digestology
  72. Targeted mutation-based therapy for intrahepatic cholangiocarcinoma
    Facai Yang, Yinghe Qiu, Bin Yi · 2023 · Hepatoma Research
  73. The morphomolecular features of cholangiocarcinoma in the personalised era
    Daniel T. Field, Guido Carpino, Michail Doukas, Timothy James Kendall · 2024 · Diagnostic histopathology
  74. Catalytically distinct IDH1 mutants tune phenotype severity in tumor models
    Mowaffaq Adam Ahmed Adam, Mikella Robinson, Ashley V. Schwartz, Grace A. Wells, An D. Hoang, Elene Albekioni, Cecilia Gallo, Grace Chao, Joi L. Weeks, Giovanni Quichocho et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  75. Molecular mechanisms of thrombotic complications in glial tumors
    Anna Savelyeva, Yu. I. Zhilenkova, Maria A. Simakova, О. В. Сироткина · 2024 · Russian Journal for Personalized Medicine
  76. Molecular profiling and next-generation sequencing applications in transplant oncology
    Nadine Soliman, David W. Victor, Ashton Anthony Connor · 2024 · Elsevier eBooks
  77. Role of genomics in liver transplantation for cholangiocarcinoma
    Nadine Soliman, Anaum Maqsood, Ashton Anthony Connor · 2025 · Current Opinion in Organ Transplantation
  78. Advances in Molecular Research on Intrahepatic Cholangiocarcinoma and the Clinical Application Value of NGS Technology in the Precision Treatment of ICC
    超 马 · 2025 · Advances in Clinical Medicine
  79. Therapeutic potential of pharmacoepigenetics in cholangiocarcinoma
    Colm J. O’Rourke, Jesper Bøje Andersen · 2025 · Elsevier eBooks
  80. Recent advances in DNA methylation in tumorigenesis and diagnosis
    Shikang Liu, Youli Yao, Zhongjun Li, Zhiyi Wang · 2025 · MedMat.
  81. Additional file 1 of Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
    Bingqi Ma, Huijuan Meng, Tian, Ye, Wang, Yingying, Song, Tianqiang, Zhang, Ti, Wu, Qiang, Cui, Yunlong, Li, Huikai, Zhang, Wei et al. · 2020 · Figshare
  82. Mechanisms of Cholangiocarcinoma, Molecular Subtypes, and Emerging Therapeutic Strategies
    Ziao Wang, Qing Zhang · 2026 · Journal of Biosciences and Medicines
  83. Update zur medikamentösen Therapie der Gallengangskarzinome
    Linde Kehmann, Tom Lüdde, Markus Sebastian Jördens, Sven Heiko Loosen, Christoph Roderburg, Catherine Leyh · 2026 · Gastroenterologie up2date
  84. Leucémies aigüs lymphoblastiques T (LAL-T) et dérégulation épigénétique
    Aurore Touzart · 2018
  85. Etude de microbiote biliaire associé aux cholangiocarcinomes (CCA) et caractérisation des mécanismes impliqués
    Massa Saab · 2021
  86. Développement de radiotraceurs spécifiques des isocitrates déshydrogénases mutées (mIDH1) pour l'imagerie TEP/TEMP des tumeurs solides
    Lucie Arnaud · 2025
  87. Systemic treatment of advanced biliary tract cancers: moving from ‘all-comers’ to precision medicine
    Amélie Mallet, Chloé Sauzay, Egidijus Morkūnas, Yann Touchefeu · 2026 · Best Practice & Research Clinical Gastroenterology
  88. Massive/massebildende duktuläre Reaktion (MDR) bei angioinvasivem hepatozellulärem Karzinom
    Anne Kristin Fischer, Reinhard Büttner, Thorsten Persigehl, Hans‐Peter Fischer · 2026 · Die Chirurgie
  89. Clinicopathological Features of Intrahepatic Cholangiocarcinoma with Assessment of IDH1 Mutation: A Two-Center Retrospective Study
    Müge Büyükaksoy, Seli̇n Aktürk Esen, Nesrin Turhan, Enes seyda Şahiner, İmdat Eroğlu, Ayşenur Sert, Ugur Ozberk, Denizcan Hastürk, Öznur Bal, Efnan Algın et al. · 2026 · Journal of Clinical Medicine
  90. The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors
    Vaibhav Sahai, Juan W. Valle, Nadim Farés, M.M. Javle, I. Ghanem, Paula Cerdá, Ilario Giovanni Rapposelli, I.G. Jimenez, MA Gonzalez-Carmona, Antoine Hollebecque et al. · 2026 · ESMO Gastrointestinal Oncology
  91. Update zur medikamentösen Therapie der Gallengangskarzinome
    Linde Kehmann, Tom Lüdde, Markus Sebastian Jördens, Sven Heiko Loosen, Christoph Roderburg, Catherine Leyh · 2026 · Onkologische Welt
  92. Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma
    Rachel N. Harvey, Rebecca Gelfer, Esther N Drill, Vinod P. Balachandran, Michael D’Angelica, Jeffrey A. Drebin, T. Peter Kingham, Lily V. Saadat, Kevin C. Soares, Alice Chia-Chi Wei et al. · 2026 · JCO Precision Oncology
  93. Isocitrate dehydrogenase (IDH) as target for anticancer therapy in brain and gastrointestinal cancers
    Virginia Agnetti, Alessandro Acunzo, Giulia Airò, Alessandro Lazzarin, Eleonora Lai, Maria Michiara, Serafina Martella, Laura Demurtas, Mario Scartozzi, Cinzia Solinas et al. · 2026 · Discover Medicine
  94. Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
    Anne B. Richardson, Payel Chatterjee, Rachele Rosati, Alex C. Rajewski, Robert L. Diaz, Lauren R. Appleyard, Shalini E. Pereira, Brady M. Bernard, Milind M. Javle, Gentry Teng King et al. · 2026 · Cancer Research Communications
  95. Intratumoral IDH1 mutation status in intrahepatic cholangiocarcinoma is homogeneous
    Sharon Weidmann, Silvana Ebner, Aayushi Srivastava, Armin Wiegering, Stefan Zeuzem, Peter Johannes Wild, Maximilian N. Kinzler, Melanie Winter, Dirk H. Walter · 2026 · Histopathology
  96. Real‐world outcomes in circulating tumor DNA–detected isocitrate dehydrogenase 1–mutant cholangiocarcinoma: First‐line gemcitabine and cisplatin with versus without immunotherapy
    Richard D. Kim, Nikolas Naleid, Adrian Bubie, Nicole J. Zhang, Keelia M. Clemens · 2026 · Cancer
  97. Development of Radioiodinated Tetrahydropyrazolopyridine Inhibitors Targeting mIDH
    Sarandeep Kaur, Sladjana Dukić-Stefanović, Lucie Arnaud, Jean‐Michel Chezal, Barbara Wenzel, Rareş‐Petru Moldovan, Klaus Kopka, Aurélie Maisonial‐Besset · 2026 · Journal of Labelled Compounds and Radiopharmaceuticals
  98. Emerging Anti-cancer Targets in Mitochondria
    Petr Ježek, Katarína Smolková, Aleš Dvořák, Tomáš Olejár · 2014 · Springer eBooks